{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:29:08Z","timestamp":1792517348501,"version":"4.5.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Symptomatic patients with Gaucher disease (GD) (acid \u03b2-glucosidase [Gcase] deficiency) are treated with injectable human recombinant GCase. Treatment results in significant decreases in lipid storage in liver, spleen, and bone marrow, but the generalized osteopenia and focal bone lesions present in many adult patients are refractory to treatment. A double-blind, 2-arm, placebo-controlled trial of alendronate (40 mg\/d) was performed in adults with GD who had been treated with enzyme for at least 24 months. Primary therapeutic endpoints were improvements in (1) bone mineral density (BMD) and content (BMC) at the lumbar spine, and (2) focal lesions in x-rays of long bones assessed by a blinded reviewer. There were 34 patients with GD type 1 (age range, 18-50 years) receiving enzyme therapy who were randomized for this study. After 18 months, \u0394BMD at the lumbar spine was 0.068 \u00b1 0.21 and 0.015 \u00b1 0.034 for alendronate and placebo groups, respectively (P = .001). Long-bone x-rays showed no change in focal lesions or bone deformities in any subject in either arm. Alendronate is a useful adjunctive therapy in combination with enzyme replacement therapy (ERT) for the treatment of GD-related osteopenia in adults, but it cannot be expected to improve focal lesions.<\/jats:p>","DOI":"10.1182\/blood-2003-11-3854","type":"journal-article","created":{"date-parts":[[2004,3,16]],"date-time":"2004-03-16T01:13:35Z","timestamp":1079399615000},"page":"1253-1257","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":96,"title":["Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy"],"prefix":"10.1182","volume":"104","author":[{"given":"Richard J.","family":"Wenstrup","sequence":"first","affiliation":[{"name":"From the Division of Human Genetics and the Department of Radiology, Children's Hospital Research Foundation, Cincinnati, OH; and the Department of Community Health, Wright State University, Dayton, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Bailey","sequence":"additional","affiliation":[{"name":"From the Division of Human Genetics and the Department of Radiology, Children's Hospital Research Foundation, Cincinnati, OH; and the Department of Community Health, Wright State University, Dayton, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A.","family":"Grabowski","sequence":"additional","affiliation":[{"name":"From the Division of Human Genetics and the Department of Radiology, Children's Hospital Research Foundation, Cincinnati, OH; and the Department of Community Health, Wright State University, Dayton, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Moskovitz","sequence":"additional","affiliation":[{"name":"From the Division of Human Genetics and the Department of Radiology, Children's Hospital Research Foundation, Cincinnati, OH; and the Department of Community Health, Wright State University, Dayton, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan E.","family":"Oestreich","sequence":"additional","affiliation":[{"name":"From the Division of Human Genetics and the Department of Radiology, Children's Hospital Research Foundation, Cincinnati, OH; and the Department of Community Health, Wright State University, Dayton, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[{"name":"From the Division of Human Genetics and the Department of Radiology, Children's Hospital Research Foundation, Cincinnati, OH; and the Department of Community Health, Wright State University, Dayton, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shumei","family":"Sun","sequence":"additional","affiliation":[{"name":"From the Division of Human Genetics and the Department of Radiology, Children's Hospital Research Foundation, Cincinnati, OH; and the Department of Community Health, Wright State University, Dayton, OH."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021222143221100_REF1","unstructured":"Beutler E, Grabowski G. Gaucher disease. In: Scriver CR, Beaudet AL, Valle D, et al, eds. The Metabolic and Molecular Basis of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001: 3635-3668."},{"key":"2020021222143221100_REF2","unstructured":"Frederickson DS, Sloan HR. Glucosyl ceramide lipidoses: Gaucher's disease. In: Stanbury JB, Wyngaarden JB, Frederickson DS, eds. The Metabolic Basis of Inherited Disease. 3rd ed. New York, NY: McGraw-Hill; 1978: 730-759."},{"key":"2020021222143221100_REF3","unstructured":"Gaucher PCE. De l'epithelioma primitif de la rate, hypertrophie idiopathique del la rate san leucemie. MD thesis, Paris, France; 1882."},{"key":"2020021222143221100_REF4","doi-asserted-by":"crossref","unstructured":"Hermann G, Goldblatt J, Levy RN, Goldsmith SJ, Desnick RJ, Grabowski GA. Gaucher's disease type 1: assessment of bone involvement by CT and scintigraphy. Am J Roentgenol.1986;147: 943-948.","DOI":"10.2214\/ajr.147.5.943"},{"key":"2020021222143221100_REF5","unstructured":"Beighton P, Goldblatt J, Sacks S. Bone involvement in Gaucher disease. Prog Clin Biol Res.1982;95: 107-129."},{"key":"2020021222143221100_REF6","doi-asserted-by":"crossref","unstructured":"Myers HS, Cremin BJ, Beighton P, Sacks S. Chronic Gaucher's disease: radiological findings in 17 South African cases. Br J Radiol.1975;48: 465-469.","DOI":"10.1259\/0007-1285-48-570-465"},{"key":"2020021222143221100_REF7","doi-asserted-by":"crossref","unstructured":"Rosenthal DI, Scott JA, Barranger J, et al. Evaluation of Gaucher disease using magnetic resonance imaging. J Bone Joint Surg [Am].1986;68: 802-808.","DOI":"10.2106\/00004623-198668060-00002"},{"key":"2020021222143221100_REF8","doi-asserted-by":"crossref","unstructured":"Cremin BJ, Davey H, Goldblatt J. Skeletal complications of type I Gaucher disease: the magnetic resonance features. Clin Radiol.1990;41: 244-247.","DOI":"10.1016\/S0009-9260(05)81657-5"},{"key":"2020021222143221100_REF9","unstructured":"Amstutz HC. The hip in Gaucher's disease. Clin Orthop.1973;90: 83-89."},{"key":"2020021222143221100_REF10","unstructured":"Draznin SZ, Singer K. Legg-Perthes' disease: a syndrome of many etiologies? With clinical and roentgenographic findings in a case of Gaucher's disease. Am J Roentgenol.1948;60: 490."},{"key":"2020021222143221100_REF11","unstructured":"Billings AA, Post M, Shapiro CM. Febrile reaction of Gaucher's disease. Ill Med J.1973;144: 222-226."},{"key":"2020021222143221100_REF12","doi-asserted-by":"crossref","unstructured":"Stowens DW, Teitelbaum SL, Kahn AJ, Barranger JA. Skeletal complications of Gaucher disease. Medicine (Baltimore).1985;64: 310-322.","DOI":"10.1097\/00005792-198509000-00003"},{"key":"2020021222143221100_REF13","doi-asserted-by":"crossref","unstructured":"Heasman PA. Mandibular lesions in Gaucher disease. Oral Surg Oral Med Oral Pathol.1991;72: 506.","DOI":"10.1016\/0030-4220(91)90569-X"},{"key":"2020021222143221100_REF14","unstructured":"Siffert RS, Platt A. Gaucher's disease: orthopaedic considerations. Prog Clin Biol Res.1982;95: 617-624."},{"key":"2020021222143221100_REF15","doi-asserted-by":"crossref","unstructured":"Pastores G, Wallenstein S, Desnick RJ, Luckey MM. Bone density in type 1 Gaucher disease. J Bone Min Res.1997;11: 1801-1807.","DOI":"10.1002\/jbmr.5650111125"},{"key":"2020021222143221100_REF16","doi-asserted-by":"crossref","unstructured":"Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med.2000;160: 2835-2843.","DOI":"10.1001\/archinte.160.18.2835"},{"key":"2020021222143221100_REF17","doi-asserted-by":"crossref","unstructured":"Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med.1991;324: 1464-1470.","DOI":"10.1056\/NEJM199105233242104"},{"key":"2020021222143221100_REF18","doi-asserted-by":"crossref","unstructured":"Pastores G, Sibille A, Grabowski GA. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in thirty-three patients treated for six to twenty-four months. Blood.1993;82: 408-416.","DOI":"10.1182\/blood.V82.2.408.408"},{"key":"2020021222143221100_REF19","doi-asserted-by":"crossref","unstructured":"Beutler E, Demina A, Laubscher K, et al. The clinical course of treated and untreated Gaucher disease: a study of 45 patients. Blood Cells Mol Dis.1995;21: 86-108.","DOI":"10.1006\/bcmd.1995.0012"},{"key":"2020021222143221100_REF20","doi-asserted-by":"crossref","unstructured":"Elstein D, Hadas-Halpern I, Itzchaki M, Lahad A, Abrahamov A, Zimran A. Effect of low-dose enzyme replacement therapy on bones in Gaucher disease patients with severe skeletal involvement. Blood Cells Mol Dis.1996;22: 101-108.","DOI":"10.1006\/bcmd.1996.0016"},{"key":"2020021222143221100_REF21","doi-asserted-by":"crossref","unstructured":"Rosenthal DI, Doppelt SH, Mankin HJ, et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics.1995;96: 629-637.","DOI":"10.1542\/peds.96.4.629"},{"key":"2020021222143221100_REF22","unstructured":"Barak V, Acker M, Nisman B, et al. Cytokines in Gaucher's disease. Eur Cytokine Netw.1999;10: 205-210."},{"key":"2020021222143221100_REF23","doi-asserted-by":"crossref","unstructured":"Harinck HI, Bijvoet OL, van der Meer JW, Jones B, Onvlee GJ. Regression of bone lesions in Gaucher's disease during treatment with aminohydroxypropylidene bisphosphonate [letter]. Lancet.1984;2: 513.","DOI":"10.1016\/S0140-6736(84)92579-0"},{"key":"2020021222143221100_REF24","doi-asserted-by":"crossref","unstructured":"Ciana G, Cuttini M, Bembi B. Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement [letter]. N Engl J Med.1997;337: 712.","DOI":"10.1056\/NEJM199709043371015"},{"key":"2020021222143221100_REF25","unstructured":"Ostlere L, Warner T, Meunier PJ, et al. Treatment of type 1 Gaucher's disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate). Q J Med.1991;79: 503-515."},{"key":"2020021222143221100_REF26","doi-asserted-by":"crossref","unstructured":"O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics.1979;35: 549-556.","DOI":"10.2307\/2530245"},{"key":"2020021222143221100_REF27","doi-asserted-by":"crossref","unstructured":"Liberman UA, Weiss SP, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Eng J Med.1995;333: 1437-1443.","DOI":"10.1056\/NEJM199511303332201"},{"key":"2020021222143221100_REF28","doi-asserted-by":"crossref","unstructured":"Watts N. Bone quality: getting closer to a definition. J Bone Miner Res.2002;17: 1148-1150.","DOI":"10.1359\/jbmr.2002.17.7.1148"},{"key":"2020021222143221100_REF29","doi-asserted-by":"crossref","unstructured":"Riggs BL, Melton LJ III. Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res.2002;17: 11-14.","DOI":"10.1359\/jbmr.2002.17.1.11"},{"key":"2020021222143221100_REF30","doi-asserted-by":"crossref","unstructured":"Chesnut CH III, Rose CJ. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res.2001;16: 2163-2172.","DOI":"10.1359\/jbmr.2001.16.12.2163"},{"key":"2020021222143221100_REF31","doi-asserted-by":"crossref","unstructured":"Adami S, Mian M, Gatti P, et al. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone.1994;15: 415-417.","DOI":"10.1016\/8756-3282(94)90818-4"},{"key":"2020021222143221100_REF32","doi-asserted-by":"crossref","unstructured":"Reid IR, Nicholson GC, Weinstein RS, et al. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial [see comments]. Am J Med.1996;101: 341-348.","DOI":"10.1016\/S0002-9343(96)00227-6"},{"key":"2020021222143221100_REF33","doi-asserted-by":"crossref","unstructured":"Chesnut CH, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med.1995;99: 144-152.","DOI":"10.1016\/S0002-9343(99)80134-X"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/5\/1253\/1700964\/zh801704001253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/104\/5\/1253\/1700964\/zh801704001253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T03:48:01Z","timestamp":1682653681000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/104\/5\/1253\/18891\/Gaucher-disease-alendronate-disodium-improves-bone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9,1]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,9,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-11-3854","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9,1]]}}}